Upcoming Investment Conferences Spotlight Foghorn Therapeutics

Foghorn Therapeutics to Spotlight Innovations at Investor Conferences
Foghorn Therapeutics Inc. (NASDAQ: FHTX), a leading biotech company, is renowned for its groundbreaking work in the field of gene therapies aimed at addressing serious diseases through the innovative correction of abnormal gene expression. Situated in CAMBRIDGE, this clinical-stage company is set to participate in two vital investor conferences that will showcase its commitment to transforming healthcare.
Conferences Involved
Foghorn’s management team will be attending the B. Riley Securities Precision Oncology and Radiopharma Conference, as well as the TD Cowen 45th Annual Health Care Conference. These platforms offer a unique opportunity for Adrian Gottschalk, the President and Chief Executive Officer, to highlight Foghorn's advancements in oncology and beyond.
B. Riley Securities Precision Oncology and Radiopharma Conference
At the B. Riley Securities Conference, scheduled for February 28, 2025, at 9 a.m. EST in New York City, Foghorn will feature in a Synthetic Lethality Panel. This panel is significant as it focuses on innovative cancer therapies that exploit specific vulnerabilities within cancer cells, offering new hope for treatment methodologies.
TD Cowen 45th Annual Health Care Conference
Following the B. Riley event, Foghorn will present at the TD Cowen Health Care Conference on March 3, 2025, at 2:30 p.m. EST in Boston. This presentation will further delve into the company’s research and product pipeline, showcasing its potential impact on healthcare.
Virtual One-On-One Meetings and Other Opportunities
On March 3, Foghorn Therapeutics will also engage in virtual one-on-one meetings for interested investors. These meetings provide an excellent chance for stakeholders to gain insights into the company's strategic goals and future direction.
Accessing Presentation Webcast
For those unable to attend, a webcast of these presentations will be accessible through the Investor section of Foghorn Therapeutics' website. This interactive platform ensures that even remote investors can stay informed about Foghorn's latest developments and innovations.
About Foghorn Therapeutics
Foghorn Therapeutics is dedicated to discovering and developing a unique class of medicines that caters to genetically defined dependencies within the chromatin regulatory system. Utilizing their advanced Gene Traffic Control platform, the company methodically studies, identifies, and validates promising drug targets within this complex area of genetics. With a focus on oncology, Foghorn Therapeutics is building a robust pipeline of product candidates, aiming to provide transformative therapies to those in need.
Foghorn’s Mission and Research Focus
Foghorn’s mission is to revolutionize treatment approaches for serious diseases through advanced gene therapies. As the understanding of genetic factors in diseases continues to grow, Foghorn is at the forefront of research that integrates these insights into practical, transformative treatments. The company continues to emphasize its commitment to innovation and patient-centered care.
Stay Connected with Foghorn Therapeutics
To learn more about Foghorn Therapeutics and their pioneering work, interested individuals can explore the company’s website at www.foghorntx.com. For the latest updates, follow Foghorn on social media platforms like X (formerly Twitter) and LinkedIn, as they share insights on their research progress and innovations.
Contact Information
If you have any inquiries, please reach out to Karin Hellsvik at Foghorn Therapeutics Inc. via email at khellsvik@foghorntx.com.
Frequently Asked Questions
What is the focus of Foghorn Therapeutics?
Foghorn Therapeutics focuses on developing gene therapies that correct abnormal gene expression to treat serious diseases, primarily in oncology.
Which upcoming conferences will Foghorn participate in?
Foghorn will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference and the TD Cowen 45th Annual Health Care Conference.
Who will present at the conferences?
Adrian Gottschalk, the President and CEO of Foghorn, will be the key presenter at both conferences.
Can I access the presentations online?
Yes, the presentations will be available via webcast on Foghorn Therapeutics' Investor section of their website for those who cannot attend in person.
How can I contact Foghorn Therapeutics for more information?
You can contact Karin Hellsvik at Foghorn Therapeutics via email at khellsvik@foghorntx.com.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.